Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

2articles mentioning institutions

2institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: NCT04294667 ×

NCT04294667

This institution is selected. Its supporting articles are shown below.

NCT042946672

Articles mentioning NCT04294667

2 articles · page 1 of 1

PO:13:336 Improvement of fatigue, musculoskeletal pain, morning stiffness and health-related quality of life in patients with SLE treated with dapirolizumab pegol: 48-week results from a phase 3 trial

lupusscimed · abstract · 2026-03-01 · 1 matching annotations

85.8%

NCT04294667 SLE SLE-specific Lupus Dapirolizumab pegol DZP prednisone LupusQoL

…), which lacks an Fc domain. In the phase 3 PHOENYCS GO trial ( NCT04294667), the primary endpoint was met; DZP plus standard of care (DZP+…

S15:02 Dapirolizumab pegol and flare reduction in patients with SLE in a 48-week phase 3 trial: an updated post hoc analysis of alternative definitions of flares that reflect clinical practice

lupusscimed · abstract · 2026-03-01 · 1 matching annotations

83.8%

NCT04294667 dapirolizumab pegol DZP BILAG-2004 prednisone

…lare frequency, using data from the phase 3 PHOENYCS GO trial ( NCT04294667) of dapirolizumab pegol (DZP).DZP, a novel CD40L inhibitor, con…